Literature DB >> 14742980

Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation.

Marie Jaksch1, Mats Remberger, Jonas Mattsson.   

Abstract

BACKGROUND: Donor T cells are primarily responsible for graft-versus-host disease (GVHD). Three effector pathways have been described for T-cell cytotoxicity: granzyme B/perforin, Fas/Fas ligand (FasL), and secreted molecules such as tumor necrosis factor (TNF)-alpha. Therefore, this study evaluates the gene expression pattern in the peripheral blood of patients after allogeneic stem cell transplantation and correlates the results to acute GVHD.
METHODS: Real-time quantitative reverse transcriptase-polymerase chain reaction was used to quantify the gene expression of granzyme B, perforin, FasL, and TNF-alpha in peripheral blood from 53 patients.
RESULTS: Samples were available from 27 of the 38 patients with acute GVHD diagnoses. Increased gene expression (>50%) during acute GVHD was detected in 23 of 27, 26 of 27, and 24 of 27 patients for granzyme B, perforin, and FasL, respectively. TNF-alpha showed a diffuse correlation. The median increases were as follows: granzyme B, 7.2x (1.6-183.2); perforin, 5.8x (1.6-254.9); and FasL, 8.5x (1.5-895.6). We also showed that all of the 10 patients with increasing levels of granzyme B, perforin, and FasL during steroid treatment demonstrated persistent or deteriorating GVHD. Patients with increasing transcription levels during cytomegalovirus (CMV) reactivation responded significantly better to therapy than those with declining levels. A total of 13 of 17 patients with increasing levels versus 0 of 11 patients with decreasing levels responded well to CMV treatment (P<0.01).
CONCLUSION: Although not specific for acute GVHD, quantitative assessment of immune transcripts may be of value in diagnosing and monitoring acute GVHD. It may also serve as a guide for the clinician in detecting patients who respond poorly to CMV therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742980     DOI: 10.1097/01.TP.0000100465.83529.42

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Authors:  Haowen Xiao; Yi Luo; Xiaoyu Lai; Shan Fu; Jimin Shi; Yamin Tan; Jingsong He; Wanzhuo Xie; Weiyan Zheng; Li-Mengmeng Wang; Lifei Zhang; Lizhen Liu; Xiujin Ye; Xiaohong Yu; Zhen Cai; Maofang Lin; He Huang
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection.

Authors:  C F Classen; P I Bird; K-M Debatin
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

3.  DNA methylation dynamics in blood after hematopoietic cell transplant.

Authors:  Ramon M Rodriguez; Beatriz Suarez-Alvarez; Rubén Salvanés; Manuel Muro; Pablo Martínez-Camblor; Enrique Colado; Miguel Alcoceba Sánchez; Marcos González Díaz; Agustin F Fernandez; Mario F Fraga; Carlos Lopez-Larrea
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.